Skip to main content

Table 3 Statistical analysis of clinicopathological variables related to SPAG5 and NuMA mRNA expressions

From: Investigation of the SPAG5 gene expression and amplification related to the NuMA mRNA levels in breast ductal carcinoma

  N (%) t SSig. (2-tailed) Std. Error 95% CI
Lower Upper
SPAG5 Age < 50 years 16(40) − 1.05 0.29 1.19 − 3.67 1.15
> 50 years 24(60)
Grade I and II 30(75) − 0.97 0.33 1.31 − 3.94 1.37
III 10(25)
LN Positive 18(45.5) 0.77 0.44 1.18 − 1.47 3.31
Negative 22(55.5
FH Positive 13(32.5) 0.78 0.43 1.25 − 1.55 3.53
Negative 27(67.5)
ER Positive 35(87.5) − 0.19 0.84 1.79 − 3.98 3.27
Negative 5(12.5)
PR Positive 33(82.5) − 0.02 0.98 1.56 − 3.20 3.12
Negative 7(17.5)
HER2 Positive 7(17.5) − 0.02 0.98 1.56 − 3.20 3.12
Negative 33(82.5)
NUMA Age < 50 years 16(40) 0.89 0.37 0.79 − 0.90 2.32
> 50 years 24(60)
Grade I and II 30(75) − 1.91 0.06 0.84 − 3.32 0.09
III 10(25)
LN Positive 18(45.5) − 1.0 0.32 0.78 − 2.37 0.79
Negative 22(55.5
FH Positive 13(32.5) − 1.93 0.06 0.80 − 3.18 0.06
Negative 27(67.5)
ER Positive 35(87.5) − 2.90 0.006 1.07 − 5.32 − 0.95
Negative 5(12.5)
PR Positive 33(82.5) − 0.79 0.43 1.03 − 2.90 1.26
Negative 7(17.5)
HER2 Positive 7(17.5) − 0.79 0.43 1.03 − 2.90 1.26
Negative 33(82.5)
  1. Independent sample t test was applied to compare the SPAG5 and NuMA gene expression levels according to clinicopathological features. Normal distribution of variables and equality of variances were checked by Kolmogorov-Smirnov and Levene’s test, respectively. The significance level was selected at 0.05.
  2. N number, t t test, sig significance (p value), Std standard, CI confidence intervals, SPAG5 sperm-associated antigen, NuMA nuclear mitotic apparatus protein, LN lymph node involvement, FH family history, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2